Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,280 questions in 114 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 37.5%Ungraded 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Solcoseryl vs antiseptic agent Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Solcoseryl vs antiseptic agent Quality of life ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Solcoseryl vs antiseptic agent Amputation ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Solcoseryl vs antiseptic agent Adverse events · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | 1 study · 35 participants | Very low |
Duoderm® (hydroactive dressing) vs antiseptic agent Complete leg ulcer closure ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Duoderm® (hydroactive dressing) vs antiseptic agent Time to closure ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Duoderm® (hydroactive dressing) vs antiseptic agent Change in ulcer size (surface area or volume) · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | 1 study · 35 participants | Very low |
Duoderm® (hydroactive dressing) vs antiseptic agent Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Isoxsuprine vs placebo Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and a leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Duoderm® (hydroactive dressing) vs antiseptic agent Quality of life ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Duoderm® (hydroactive dressing) vs antiseptic agent Amputation ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Duoderm® (hydroactive dressing) vs antiseptic agent Adverse events · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | 1 study · 35 participants | Ungraded |
Isoxsuprine vs placebo Quality of life ‐ not reported · individuals with sickle cell disease and a leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Isoxsuprine vs placebo Amputation ‐ not reported · individuals with sickle cell disease and a leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Isoxsuprine vs placebo Adverse events ‐ not reported · individuals with sickle cell disease and a leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Arginine butyrate plus standard care alone vs standard care alone Complete leg ulcer closure (defined as 100% epithelization or skin closure without drainage) · individuals with sickle cell disease and a leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | RR 3.72 [0.9, 15.35] | 1 study · 23 participants | Very low |
Arginine butyrate plus standard care alone vs standard care alone Time to ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Standard rhGH vs placebo FEV1 (% predicted) change since baseline · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 1 study · 43 participants | Low |
Standard rhGH vs no treatment Height velocity (cm/year) · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 4 studies · 156 participants | Very low |
Standard rhGH vs no treatment Weight (kg) Change from baseline · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 1 study · 62 participants | Very low |
Standard rhGH vs no treatment QoL Change from baseline · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 1 study · 57 participants | Very low |
Standard rhGH vs no treatment Fasting blood glucose (mg/dL) · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 3 studies · 92 participants | Very low |
Standard rhGH vs no treatment Number of pulmonary exacerbations or hospitalisations · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 3 studies · 94 participants | Very low |
High‐dose rhGH vs placebo FEV1 (% predicted) Change from baseline · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 1 study · 41 participants | Low |
High‐dose rhGH vs placebo FVC (% predicted) Change from baseline · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 1 study · 41 participants | Low |
High‐dose rhGH vs placebo Height velocity (cm/year) · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 1 study · 41 participants | Low |
High‐dose rhGH vs placebo Weight (kg) Change from baseline · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 1 study · 41 participants | Low |
High‐dose rhGH vs placebo QoL · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 1 study · 41 participants | Very low |
Standard rhGH vs placebo FVC (% predicted) change since baseline · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 1 study · 43 participants | Low |
High‐dose rhGH vs placebo Fasting blood glucose (mg/dL) · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 1 study · 41 participants | Low |
High‐dose rhGH vs placebo Number of pulmonary exacerbations or hospitalisations · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | RR 1.92 [0.66, 5.61] | 1 study · 42 participants | Low |
High‐dose rhGH vs standard‐dose rhGH FEV1 (% predicted) Change from baseline · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 1 study · 42 participants | Low |
High‐dose rhGH vs standard‐dose rhGH FVC (% predicted) Change from baseline · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 1 study · 42 participants | Low |
High‐dose rhGH vs standard‐dose rhGH Height velocity (cm/year) · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 1 study · 42 participants | Low |
High‐dose rhGH vs standard‐dose rhGH Weight (kg) Change from baseline · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 1 study · 42 participants | Low |
High‐dose rhGH vs standard‐dose rhGH QoL · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | NR | No studies |
High‐dose rhGH vs standard‐dose rhGH Fasting blood glucose (mg/dL) · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 1 study · 42 participants | Low |
High‐dose rhGH vs standard‐dose rhGH Number of pulmonary exacerbations or hospitalisations · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | RR 1.28 [0.52, 3.18] | 1 study · 42 participants | Low |
Standard rhGH vs placebo Height velocity (cm/year) · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 1 study · 43 participants | Low |
Standard rhGH vs placebo Weight (kg) Change from baseline · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 1 study · 43 participants | Low |
Standard rhGH vs placebo QoL · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | NR | Very low |
Standard rhGH vs placebo Fasting blood glucose (mg/dL) · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 1 study · 43 participants | Low |
Standard rhGH vs placebo Number of pulmonary exacerbations or hospitalisations · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | RR 1.5 [0.49, 4.59] | 1 study · 44 participants | Low |
Standard rhGH vs no treatment FEV1(% predicted) · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 1 study · 19 participants | Very low |
Standard rhGH vs no treatment FVC (% predicted) · children and young adults with CF Recombinant growth hormone therapy for cystic fibrosis in children and young adults (2021) · Cochrane | no estimate extracted | 1 study · 19 participants | Very low |
ACE inhibitors vs placebo Urinary protein or albumin excretion ‐ total albumin excretion at 6 months · adults and children with proteinuria or microalbuminuria due to sickle cell disease Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle… (2021) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |
ACE inhibitors vs placebo Serum creatinine · adults and children with proteinuria or microalbuminuria due to sickle cell disease Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle… (2021) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |
ACE inhibitors vs placebo Electrolyte levels · adults and children with proteinuria or microalbuminuria due to sickle cell disease Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle… (2021) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |
ACE inhibitors vs placebo Mean blood pressure (mmHg) · adults and children with proteinuria or microalbuminuria due to sickle cell disease Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle… (2021) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |
ACE inhibitors vs placebo Hemoglobin concentration (g/dL) · adults and children with proteinuria or microalbuminuria due to sickle cell disease Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle… (2021) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |